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cell-derived human brain microvascular 
endothelial cells
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Abstract 
Background: Cerebral hypoxia/ischemia (H/I) is an important stress factor involved in the disruption of the blood–
brain barrier (BBB) following stroke injury, yet the cellular and molecular mechanisms on how the human BBB 
responds to such injury remains unclear. In this study, we investigated the cellular response of the human BBB to 
chemical and environmental H/I in vitro.
Methods: In this study, we used immortalized hCMEC/D3 and IMR90 stem‑cell derived human brain microvascular 
endothelial cell lines (IMR90‑derived BMECs). Hypoxic stress was achieved by exposure to cobalt chloride (CoCl2) or 
by exposure to 1 % hypoxia and oxygen/glucose deprivation (OGD) was used to model ischemic injury. We assessed 
barrier function using both transendothelial electrical resistance (TEER) and sodium fluorescein permeability. Changes 
in cell junction integrity were assessed by immunocytochemistry and cell viability was assessed by trypan‑blue exclu‑
sion and by MTS assays. Statistical analysis was performed using one‑way analysis of variance (ANOVA).
Results: CoCl2 selectively disrupted the barrier function in IMR90‑derived BMECs but not in hCMEC/D3 monolayers 
and cytotoxic effects did not drive such disruption. In addition, hypoxia/OGD stress significantly disrupted the barrier 
function by selectively disrupting tight junctions (TJs) complexes. In addition, we noted an uncoupling between cell 
metabolic activity and barrier integrity.
Conclusions: In this study, we demonstrated the ability of IMR90‑derived BMECs to respond to hypoxic/ischemic 
injury triggered by both chemical and environmental stress by showing a disruption of the barrier function. Such dis‑
ruption was selectively targeting TJ complexes and was not driven by cellular apoptosis. In conclusion, this study sug‑
gests the suitability of stem cell‑derived human BMECs monolayers as a model of cerebral hypoxia/ischemia in vitro.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The blood–brain barrier (BBB), a component of the neu-
rovascular unit, constitutes a crucial biological barrier in 
the maintenance of brain homeostasis by restricting the 
diffusion of solutes and toxins to brain parenchyma. The 
presence of such barrier is supported by brain microvas-
cular endothelial cells (BMECs), which are present in the 
cerebral microvasculature. BMECs provide both a physi-
cal (tight junctions complexes) and a chemical barrier 
(drug and nutrient transporters), which tightly regulate 
the diffusion of small molecules between the blood and 
brain. However, the integrity of the BBB is compromised 
in several neurological diseases including multiple scle-
rosis [1], neurodegenerative diseases [2–5], and stroke [1, 
6, 7].
Stroke constitutes the fifth leading cause of death in 
industrialized countries and is a leading cause of disabil-
ity [8]. The majority of stroke events are classified as an 
ischemic, marked by an abrupt decreased perfusion in a 
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defined brain region, resulting in an impairment of both 
oxygen and nutrient supply. This ultimately leads to the 
onset of a cerebral hypoxic/ischemic (H/I) injury.
BMECs are the first cell type of the neurovascular to 
sense hypoxia and respond to such injury by disrupting 
barrier function. Such disruption will eventually lead to a 
vascular leakage. The mechanisms by which H/I impacts 
barrier function have been extensively studied in rodents 
and non-human primates [9–17], yet the literature show-
ing similar outcomes at the human BBB remains unclear.
In this study, we investigated the effect of H/I on a stem 
cell-derived model of the human BBB using the IMR90-
c4 induced pluripotent stem cell line [18–21] and com-
pared their response to hCMEC/D3, an immortalized 
human BMEC line commonly used in the literature [22].
Methods
Cell culture
hCMEC/D3 cell line [22] was purchased from Mil-
lipore (EMD Millipore, Billerica, MA, USA) and main-
tained following established manufacturer protocol. 
IMR90-c4 induced pluripotent stem cell (iPSC) cell line 
[18] was purchased from WiCell (WiCell, Madison, 
WI). IMR90-c4 iPS cell line was maintained in mTeSR1 
(Stem Cell Technologies, Vancouver, BC, USA) and 
grown on hPSC-qualified Matrigel (Corning Inc., Corn-
ing, NY, USA). The IMR90 cell line was differentiated 
into BMECs (iPSC-BMECs) following the differentiation 
protocol established by Lippmann and colleagues [20, 
21] and summarized in Additional file  1:  Figure  S1. In 
brief, cells were seeded at 20,000 cells/cm2 5 days before 
differentiation and maintained in mTeSR medium. Five 
days after seeding, BMECs differentiation was set using 
unconditioned maturation medium (UMM) following 
the same composition as previously described: DMEM/
F12 with 15  mM HEPES supplemented with 20  % KO 
serum replacement, 1  % MEM non-essential aminoac-
ids, and 0.5 % Glutamax I, (ThermoFisher, Waltham, MA, 
USA) and 0.1 mM β-mercaptoethanol (Sigma-Aldrich, St 
Louis, MO, USA) for 6  days. After such differentiation, 
IMR90-derived BMECs were incubated in presence EC 
differentiation medium (EC serum free medium (Ther-
moFisher), supplemented with 1 % platelet-poor derived 
plasma serum (ThermoFisher), 20  µg/mL human basic 
fibroblast growth factor (R&D Systems) and 10  µM all-
trans retinoic acid (Sigma-Aldrich) for 2  days. After 
8 days of differentiation, cells were enzymatically dissoci-
ated and seeded at a density of 106 cells/cm2 on 12-well 
Transwell polyester cell culture inserts (0.4  µm pore 
size) coated with collagen from human placenta (Sigma-
Aldrich) and fibronectin from bovine plasma (Sigma-
Aldrich) at concentrations of 80 and 20  µg/cm2. After 
24 h (day 9), BMECs were maintained in EC differentia-
tion medium containing only 1  % platelet-poor plasma-
derived serum. All experiments were carried out 48  h 
after seeding.
Barrier function
Cells were grown on 12-well Transwell polyester mem-
branes (Corning Inc.) coated with 30  µg/cm2 collagen 
I (Sigma-Aldrich, St Louis, MO, USA) or with 80  µg/
cm2 collagen supplemented with 20  µg/cm2 fibronec-
tin (Sigma-Aldrich) mixture to allow hCMEC/D3 and 
IMR90-derived BMECs to attach respectively. Mon-
olayer tightness was assessed by measuring transendothe-
lial electrical resistance (TEER) using an EVOM STX2 
chopstick electrode (World Precision Instruments, Sara-
sota, FL, USA). Paracellular permeability was assessed in 
monolayers by measuring the diffusion profile of 1 µM of 
sodium fluorescein (Sigma-Aldrich) using the clearance 
method described by Perriere and colleagues [23]. Fluo-
rescence was assessed using a Synergy MX2 ELISA plate 
reader (Bio-Tek Instruments, Burlington, VT, USA). Aver-
age TEER and permeability values of both monolayers can 
be found in Table 1. TEER and permeability values from 
untreated monolayers were used to normalize experi-
mental values expressed as % of control. Untreated group 
experimental values were arbitrarily set to 100 % control.
Cobalt chloride and hypoxic treatment
Cobalt chloride (CoCl2, MP Biomedicals, Santa Ana, CA, 
USA) was freshly dissolved in complete cell medium at 
a stock concentration of 100  mM and further dissolved 
to achieve the concentrations of 10, 30 and 100  μM. 
Cells were incubated in presence of CoCl2 for 24 h. For 
the hypoxic experiments, cell medium was replaced with 
fresh medium and cells were incubated in a normobaric 
hypoxic C-chamber (Biospherix, Laconia, NY, USA) set 
at 1 % O2, 5 % CO2 and maintained at 37 °C for 6 or 24 h. 
In experiments involving oxygen deprivation (OD), cell 
medium was replaced with Dulbecco’s Modified Eagle 
Medium (DMEM) containing 1  g/L d-glucose and 1  % 
Table 1 Biological values of hCMEC/D3 and IMR90-derived 
BMECs under resting conditions
Average cell density, TEER, fluorescein permeability (Pe) and metabolic activity 
(MTS absorbance at 490 nm wavelength). Mean ± SD, n = 18 for TEER and Pe 
values
Cell type hCMEC/D3 IMR90-derived  
BMECs
Cell density (× 103 cells/cm2) 128 ± 21 98 ± 19
TEER (Ω cm2) 40 ± 14 392 ± 113
Pe fluorescein (10−4 cm/min) 19 ± 8 2.44 ± 1.12
Metabolic activity (OD 490 nm) 1.26 ± 0.45 0.89 ± 0.34
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platelet-poor derived serum (Alfa Aesar, Ward Hill, MA, 
USA). In GD and OGD experiments, glucose-free and 
pyruvate-free DMEM were used instead of DMEM con-
taining 1 g/L d-glucose.
Immunocytochemistry
Cells were grown to confluence on 48-well coated plates 
and quickly washed with ice-cold phosphate buffered 
saline (PBS) solution and fixed with either 4 % paraform-
aldehyde (Electron Microscopy Sciences, Hatfield, PA, 
USA) or cold methanol (ThermoFisher) and processed as 
previously described [20, 21].
Cell density and viability assay
Cell density was assessed on monolayers by Trypan-
blue exclusion based assay. In brief, monolayers were 
briefly washed with ice-cold PBS and incubated in pres-
ence of accutase (corning) or 0.25  % trypsin–EDTA 
(ThermoFisher) for 5  min followed by a centrifuga-
tion at 1000  rpms for 5 min. Cells were resuspended in 
0.5 mL PBS and counted using a Countess II automated 
cell counter (ThermoFisher). Cell viability was assessed 
by MTS-based CellTiter 96® Aqueous (Promega, Madi-
son, WI, USA). After treatment, cells grown on 96-well 
plates were incubated in presence of MTS reagent for 
1 h. Absorbance was measured at 490 nm and corrected 
against unconditioned medium containing the same 
amount of MTS. Absorbance values from all samples 
were normalized against their respective control samples.
Statistics
All experiments were performed using cells coming from 
at least three independent experiments (distinct cell pas-
sages, each experiment was performed with two techni-
cal replicates). Statistical analysis was performed using 
one-way ANOVA followed by a post hoc analysis using 
Dunnett’s test with the control group as the reference 
group. P values lesser or equal to 0.05 were considered 
statistically significant.
Results
CoCl2 induces barrier disruption in IMR90-derived BMECs 
but not in hCMEC/D3 monolayers
In order to demonstrate the suitability of IMR90-derived 
BMECs (iPSC-BMECs) as an in  vitro model of cerebral 
hypoxia/ischemia, it is important to show that such 
cells can respond to known hypoxic stimuli. Thus, we 
first assessed the cellular response of iPSC-BMEC mon-
olayers to chemical hypoxia (Fig.  1) by exposing them 
to different concentrations of cobalt chloride (CoCl2), 
a common hypoxia-mimetic chemical used in vari-
ous cell types [9, 24–29]. We compared iPSC-BMECs 
response to hCMEC/D3 cell monolayers, a human brain 
microvascular endothelial cell line commonly used in 
the literature [22, 30–32]. It should be noted that these 
cell monolayers have lower baseline TEERs and higher 
sodium fluorescein permeabilities that the iPSC-BMEC 
monolayers (Table 1).
Upon exposure of 24 h to CoCl2, there was a decrease 
in the iPSC-BMECs barrier function as noted by a signifi-
cant decrease in TEER (Fig. 1a) in cells treated with CoCl2 
at 30 and 100 µM. However, hCMEC/D3 failed to display 
any changes in barrier function even when exposed at 
100  µM (a dose known to trigger a barrier breakdown 
in rat brain endothelial cell monolayers [9]). To further 
confirm this observation, we investigated changes in 
sodium fluorescein permeability in both iPSC-BMECs 
monolayers and hCMEC/D3 following CoCl2 treatment 
(Fig. 1b). As observed in our previous experiment, CoCl2 
treatment affected the barrier integrity in iPSC-BMECs 
at 30 and 100  µM, with a 3- to 4-fold increase in para-
cellular permeability to sodium fluorescein compared to 
untreated cells.
CoCl2 treatment differentially affects cell density 
and metabolism in hCMEC/D3 and IMR90-derived BMEC 
monolayers
Because CoCl2 treatment can induce cell apoptosis in 
various mammalian cell lines [33–36], we investigated 
changes in cell viability following CoCl2 treatment using 
MTS and Trypan-blue exclusion assays (Fig. 1c, d). After 
24  h of CoCl2 treatment, we did not note a significant 
decrease in hCMEC/D3 cell density (Fig.  1c). However, 
we noted a 50  % decrease in cell density only in iPSC-
BMEC group exposed to 100 µM, suggesting a detrimen-
tal effect of CoCl2 on the monolayer integrity. However, 
no change in hCMEC/D3 cell monolayer density was 
observed, even at the highest CoCl2 concentration.
Attempts to use trypan blue exclusion assay only pro-
vided information on adherent cells remaining after 
CoCl2 treatment. Furthermore, the additional mechanical 
stress applied to assess cell viability in non-adherent cells 
using such method may also interfere with the method 
accuracy. Therefore, we consider such method not suited 
for cytotoxic assays. Notably, tetrazolium-based cyto-
toxic assays directly assess changes in mitochondrial 
activity and can be directly applied to adherent and non-
adherent cells. Therefore, we investigated changes in cell 
viability following CoCl2 treatment using an MTS-based 
assay (Fig.  1d), an assay commonly used to assess cyto-
toxicity by measuring changes in cell metabolic activity 
[37]. Notably, we did not notice changes in cell viability 
in iPSC-BMEC monolayers following exposure to CoCl2 
compared to control. We even noted an increase in cell 
viability following 30 µM and 100 µM treatment. In con-
trast, we noted a dose-dependent decrease in cell viability 
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in hCMEC/D3 monolayer with a 50  % decrease in cell 
metabolism.
To further understand how CoCl2 impacted barrier 
function in iPSC-BMECs, we investigated changes in 
cell junction integrity by immunocytochemistry (Fig. 2). 
At 30 µM, we observed alterations in the distribution of 
tight junction complexes (claudin-5 and occludin) with a 
loss of immunostaining at the cell borders and a relocali-
zation into cell cytoplasm. Surprisingly, such relocaliza-
tion was not observed in adherens junction complexes 
(PECAM-1 and β-catenin). Taken together, these obser-
vations are consistent with observations in RBE4 mon-
olayers [9] and suggest the ability of IMR90-derived 
BMECs to respond to hypoxic stimulus in similar fashion 
to rodent-based in vitro models.
Hypoxia induces barrier disruption in both IMR90-derived 
BMECs and hCMEC/D3 cell monolayers
Hypoxia-induced BBB disruption is a well-established 
phenomenon reported in both in vitro and in vivo mod-
els [9, 38–44]. Therefore, we assessed the ability of both 
IMR90-derived BMECs and hCMEC/D3 to respond to 
hypoxic stress by exposing our monolayers to 1 % O2 for 
6 or 24 h (Fig. 3).
Acute (6  h) hypoxic stress resulted in significant 
decrease of over 70 % in TEER in hCMEC/D3 monolay-
ers (Fig.  3a), whereas IMR90-derived BMECs showed 
only a mild decrease. However, such changes in TEER 
were not reflected in changes in vascular permeability, 
as we noted no significant increase in sodium fluorescein 
permeability (Fig. 3b).
In contrast, prolonged hypoxic (24 h) injury resulted in 
loss of barrier function in both IMR90-derived BMECs 
and hCMEC/D3, as we observed a 50 % decrease in TEER 
(Fig. 3a) and a 2.5-fold increase in fluorescein permeabil-
ity (Fig.  3b) compared to normoxic monolayers. These 
results suggest the ability of the monolayers to respond to 
hypoxia similarly to the existing literature.
To further understand how hypoxia affects the bar-
rier function, we investigated changes in cell junction 
complexes in IMR90-derived BMECs by immunocy-
tochemistry (Fig. 3c). After 24 h of hypoxia, we did not 
Fig. 1 Cobalt chloride induces barrier disruption in iPSC‑derived BMECs but not in hCMEC/D3 monolayers. Cells were treated with cobalt chloride 
(CoCl2) for 24 h and were compared to untreated cell monolayers. Changes in the monolayer integrity were assessed by TEER (a) and by sodium 
fluorescein (b). Note the decrease in barrier function in IMR90‑derived BMECs (iPSC‑BMEC) versus the hCMEC/D3 monolayers. c Cobalt chloride 
induced decrease in adherent cell density in iPSC‑BMEC at high concentrations (100 µM). * and ** denotes P < 0.05 and P < 0.01 versus control 
(untreated) groups. d Metabolic activity following treatment with CoCl2 did not induce cell toxicity in IMR90‑derived BMECs, as we noted no 
decrease versus control group. Mean ± SD, n = 3 for each group, * and ** denotes P < 0.05 and P < 0.01 versus control (untreated) groups
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observe any changes in adherens junction (PECAM-1 
and β-catenin) complexes. However, we noted changes 
in tight junction (claudin-5 and occludin) complexes with 
a discontinuous staining pattern. Finally, we assessed by 
MTS whether this insult impacted cell viability (Fig. 3d). 
Following 24 h of hypoxic stress, we did not find any sig-
nificant changes in cell metabolic activity, as the average 
metabolic activity was 80 and 70 % of the normoxic lev-
els in IMR90-derived BMECs and hCMEC/D3 monolay-
ers, respectively. In conclusion, our data demonstrate 
that IMR90-derived BMECs, as well as hCMEC/D3 cell 
monolayers, actively respond to hypoxia by disruption 
of their barrier function. Such disruption appears driven 
by alterations in the tight junction complexes rather than 
cell death.
Oxygen-glucose deprivation impairs barrier function 
in both IMR90-derived BMECs and hCMEC/D3 monolayers
Next, we investigated how hypoxia/aglycemia affected 
the barrier function in our human models of the BBB by 
exposing our cells to hypoxia, aglycemia or to oxygen-
glucose deprivation (OGD) stress (Fig.  4). Interestingly, 
incubation in glucose-deprived medium (GD) for 24  h 
resulted in a significant decrease in TEER (~50  %) in 
both hCMEC/D3 and IMR90-derived BMEC monolay-
ers (Fig. 4) but failed to show any significant increase in 
cell permeability to sodium fluorescein (Fig. 4b) suggest-
ing that aglycemia alone was not sufficient to induce BBB 
disruption. On the other hand, hypoxia (OD) was capa-
ble of inducing BBB disruption, as we noted a significant 
decrease in TEER and an increase in when fluorescein 
permeability. However, we observed the maximum dis-
ruption cells were subjected to both oxygen and glucose 
deprivation (OGD), as noted by the lowest TEER values 
(20 % of control) and highest permeability values to fluo-
rescein (5-fold increase).
Following such observations, we investigated changes 
in cell junction complexes in IMR90-derived BMECs fol-
lowing OGD stress by immunocytochemistry (Fig.  4c). 
OGD stress was capable of altering adherens junction 
complexes (as noted by a decrease in VE-cadherin immu-
noreactivity) but more importantly, we noted a complete 
loss of immunoreactivity for tight junction complex 
proteins.
Fig. 2 Cobalt‑chloride treatment impact monolayer integrity in iPSC‑derived BMECs. Representative immunocytochemistry micrograph pictures of 
IMR90‑derived BMECs monolayers in presence of CoCl2. Cells were treated with different CoCl2 concentrations. Note the presence of irregular pat‑
terning in TJ proteins (claudin‑5 and occludin) as marked by asterisks at 30 µM treatment and a complete disruption at 100 µM. Scale bar = 20 µm
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Fig. 3 Prolonged Hypoxia impairs the barrier function in both cell monolayers. TEER (a) and sodium fluorescein (b) permeability values in both 
iPSC‑BMECs and hCMEC/D3 cell monolayers following exposure to hypoxia for 6 and 24 h. Note the early onset of hypoxia‑induced barrier disrup‑
tion in hCMEC/D3 at 6 h as indicated by TEER compared to IMR90‑derived BMECs, with a significant decrease at 24 h. Hypoxia‑induced paracellular 
permeability however was only observed after 24 h in both groups. c Immunocytochemistry profile of IMR90‑derived BMECs following exposure 
to hypoxia (1 % O2) for 24 h. Note the decreased immunoreactivity of claudin‑5 and occludin following hypoxia, whereas no changes where noted 
in other cell junction proteins (β‑catenin and PECAM‑1). Scale bar = 20 µm. d Cell metabolic activity as measured by MTS assay. Following hypoxic 
incubation, MTS was added to the cell conditioned medium and incubated for 1 h before readout. Mean ± SD, n = 3 for each group. * and ** 
denotes P < 0.05 and P < 0.01 to controls (labeled as 0 h) respectively
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Taken together, loss of tight junction complexes during 
OGD stress may be a contributor to the BBB disruption.
As changes in cell density and viability may impact the 
barrier integrity during injury, we investigated changes 
in cell density by trypan-blue exclusion assay (Fig.  4d). 
Interestingly, we noted a significant decrease in cell den-
sity after aglycemic treatment in both IMR90-derived 
BMECs and in hCMEC/D3 monolayers. However, we did 
Fig. 4 OGD induced barrier disruption in human BMECs.TEER (a) and sodium fluorescein (b) permeability values in both iPSC‑BMECs and hCMEC/
D3 cell monolayers following aglycemic (GD), hypoxic (OD) and oxygen‑glucose deprivation (OGD) stress. Cells incubated in DMEM with glucose 
under normoxia served as control. Note the increase in fluorescein permeability following OD and OGD stress. c Representative immunocytochem‑
istry pictures in iPSC‑derived BMECs monolayers following 24 h of OGD stress. Note the overall degradation in cell junctions, with a quasi‑disap‑
pearance in TJ complexes immunoreactivity. Scale bar = 20 µm. d IMR90‑derived BMECs and hCMEC/D3 average cell density following treatment 
with aglycemia, hypoxia or OGD stress. Notably, aglycemia (GD) showed the lowest cell density in both cell monolayers. e Cell metabolic activity 
following 24 h of treatment. After 24 h of treatment, MTS reagent was added to conditioned cell medium and allowed to further incubate for 1 h. 
Mean ± SD, n = 3 for each group. * and ** denotes P < 0.05 and P < 0.01 to controls (DMEM with glucose, normoxia) respectively
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not notice a significant decrease in cell density follow-
ing hypoxia and OGD stress (two conditions shown to 
have an impact on the barrier function). Furthermore, we 
observed a similar outcome when we measured changes in 
cell viability by MTS assay (Fig. 4e). Aglycemia decreased 
metabolic activity level by 60 % compared to controls in 
both monolayers. However, hypoxia (OD) alone showed 
no differences compared to controls. Finally, cells exposed 
to OGD stress showed only 15–20  % of the metabolic 
activity observed in the control group. Taken together, our 
study demonstrates that both IMR90-derived BMECs and 
hCMEC/D3 respond to OGD stress with disrupted bar-
rier function. However, we noted an uncoupling between 
BBB barrier function and cell density/cell metabolic activ-
ity following hypoxic or aglycemic treatment.
Discussion
Stroke constitutes the fifth leading cause of death and it is 
a major cause of disability in the United States. Although 
important efforts have been made to identify therapeu-
tics capable of improving outcome in stroke patients, 
the ability to translate findings from animal models to 
patients has had little success.
Human Induced pluripotent stem cells (iPSCs) based 
in  vitro models of the neurovascular unit (integrating 
BMECs, astrocytes and neurons) may help provide a 
screening platform to improve such translation. How-
ever, pluripotent stem cells are also highly hypoxic toler-
ant [45], therefore questioning the suitability of stem-cell 
based models for understanding the effects of hypoxic/
ischemic injury in vitro.
In this study, we investigated the ability of stem cell 
derived BMECs to respond to hypoxic/ischemic injury 
in  vitro by comparing their response to hCMEC/D3, 
an immortalized adult human BMEC line [22]. We first 
investigated changes in the barrier function following 
CoCl2 treatment, a chemical commonly used to simulate 
a hypoxic response in mammalian cells [25, 26, 28, 29]. 
We noted a significant decrease in barrier function in 
IMR90-derived BMECs and a loss of monolayer integrity. 
Such results are in agreement with a previous study by 
Engelhardt and colleagues [9]. In that study, the authors 
observed that CoCl2 was capable of significantly decreas-
ing barrier function in RBE4 cells monolayers as early 
as 6  h. In contrast to their findings, we observed a sig-
nificant decrease in the barrier function only after 24 h in 
IMR90-derived BMECs. Surprisingly, we did not observe 
a response in hCMEC/D3 monolayers following CoCl2 
exposure, with no changes in barrier function compared 
to untreated groups.
A difference in response to CoCl2 between the two 
monolayers might be explained by differences in oxy-
gen sensing, as CoCl2 exerts its activity through the 
activation of the hypoxia-induced factor (HIF)-1 path-
way. Such differences maybe also inherent to the nature 
of the hCMEC/D3 cells, as Patak and colleagues reported 
an absence of up-regulation in ABCB1 and ABCC1 
expression following hypoxic stress [46]. We are cur-
rently investigating such dimorphism in oxygen sensing 
between these two cells by comparing HIF-1α expression 
at protein levels and VEGF production.
Following these observations, we investigated the cel-
lular response to environmental hypoxia by incubating 
cells in the presence of 1  % O2, a gas phase concentra-
tion commonly used in the literature. In our study, both 
IMR90-derived BMECs and hCMEC/D3 cells responded 
to prolonged hypoxic injury in vitro with decreased bar-
rier function. Furthermore, IMR90-derived BMECs dis-
played alterations in tight junction complex distribution 
similar to previous reports [9]. However, oxygen-glucose 
deprivation (OGD) stress was necessary to achieve a 
major barrier disruption in both IMR90-derived BMECs 
and hCMEC/D3 cells. Such disruption was marked by 
the greatest decrease in TEER and highest increase in 
fluorescein permeability.
This dramatic decrease in barrier function was likely 
due to a major disruption in tight junction complex integ-
rity, as we noted a significant decrease in immunoreac-
tivity of both claudin-5 and occludin in IMR90-derived 
BMECs. We speculate such decreased immunoreactiv-
ity may be indicative of a cleavage of such proteins by a 
select number of matrix metalloproteinases (MMPs), in 
particular by MMP-2 and MMP-9 [47–49].
In addition to changes in barrier function due to 
changes in MMP activity, we also speculate that impaired 
energy production during hypoxic/ischemic injury may 
contribute to barrier disruption. A recent study by Van-
dekeere and colleagues suggests ATP production in brain 
endothelial cell metabolism is driven by glycolysis under 
aerobic conditions [50]. MTS-based assays are designed 
to measure changes in mitochondrial hydrogenase activ-
ity [51]. Thus, we were expecting little change in MTS 
activity following hypoxic/OGD stress in our model. Sur-
prisingly, we noted no changes in MTS activity in hypoxic 
cells. Such results were consistent with a recent study 
published by Ogunshola and colleagues [10], in which no 
significant changes in cell metabolism were observed fol-
lowing prolonged hypoxia.
Interestingly, we noted changes in cell density following 
CoCl2 treatment as well as during glucose deprivation. 
Although a decrease in cell density was accompanied 
by an increase in permeability following CoCl2 treat-
ment, we did not observe such phenomenon in glucose-
deprived cells.
Finally, we observed a conundrum between metabolic 
activity and barrier function in BMECs, in particular 
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between hypoxic and aglycemic treatments. Decreased 
cell metabolism in aglycemic cells was not accompanied 
by decreased barrier function, whereas we noted a loss 
of barrier function was not accompanied by a decrease 
in cell metabolism. Such data suggests that tight junc-
tion disruption following hypoxia may not be due to 
energy deficiency, but also suggests that IMR90-derived 
BMECs may utilize other nutrients to maintain mito-
chondrial activity through some anaploretic reactions (in 
particular glutamine). Thus, we are currently investigat-
ing how hypoxia/OGD stress influences energy produc-
tion in BMECs; in particular we are investigating how 
such stress influences changes in glycolysis and oxidative 
phosphorylation mechanism.
Conclusions
In summary, this study demonstrates the suitability of 
stem cell-derived in vitro model of the human BBB as an 
in vitro model for H/I. This model may effectively com-
plement existing in  vivo models and help improve the 
identification of novel therapeutics capable of fighting 
H/I-induced BBB disruption following stroke.
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